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Epigenome Wide Association Study of SNP–CpG Interactions on Changes in
Triglyceride Levels after Pharmaceutical Intervention: A GAW20 Analysis
Abstract
In the search for an understanding of how genetic variation contributes to the heritability of common
human disease, the potential role of epigenetic factors, such as methylation, is being explored with
increasing frequency. Although standard analyses test for associations between methylation levels at
individual cytosine-phosphateguanine (CpG) sites and phenotypes of interest, some investigators have
begun testing for methylation and how methylation may modulate the effects of genetic polymorphisms
on phenotypes. In our analysis, we used both a genome-wide and candidate gene approach to investigate
potential single-nucleotide polymorphism (SNP)–CpG interactions on changes in triglyceride levels.
Although we were able to identify numerous loci of interest when using an exploratory significance
threshold, we did not identify any significant interactions using a strict genomewide significance
threshold. We were also able to identify numerous loci using the candidate gene approach, in which we
focused on 18 genes with prior evidence of association of triglyceride levels. In particular, we identified
GALNT2 loci as containing potential CpG sites that moderate the impact of genetic polymorphisms on
triglyceride levels. Further work is needed to provide clear guidance on analytic strategies for testing
SNP–CpG interactions, although leveraging prior biological understanding may be needed to improve
statistical power in data sets with smaller sample sizes.
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Abstract
In the search for an understanding of how genetic variation contributes to the heritability of common human
disease, the potential role of epigenetic factors, such as methylation, is being explored with increasing frequency.
Although standard analyses test for associations between methylation levels at individual cytosine-phosphateguanine (CpG) sites and phenotypes of interest, some investigators have begun testing for methylation and how
methylation may modulate the effects of genetic polymorphisms on phenotypes. In our analysis, we used both a
genome-wide and candidate gene approach to investigate potential single-nucleotide polymorphism (SNP)–CpG
interactions on changes in triglyceride levels. Although we were able to identify numerous loci of interest when
using an exploratory significance threshold, we did not identify any significant interactions using a strict genomewide significance threshold. We were also able to identify numerous loci using the candidate gene approach, in
which we focused on 18 genes with prior evidence of association of triglyceride levels. In particular, we identified
GALNT2 loci as containing potential CpG sites that moderate the impact of genetic polymorphisms on triglyceride
levels. Further work is needed to provide clear guidance on analytic strategies for testing SNP–CpG interactions,
although leveraging prior biological understanding may be needed to improve statistical power in data sets with
smaller sample sizes.

Background
Methylation plays a major role in gene regulation through
epigenetic modifications at specific cytosine-phosphateguanine (CpG) residues within the regulatory regions of
genes and, consequently, may influence the transcriptional
activity [1]. In brief, methylation occurs when a methyl
group is transferred to the DNA via a family of DNA
methyltransferases. The majority of DNA methylation
occurs oncytosines, which immediately precedea guanine nucleotide (ie, CpG site). These CpG sites occur
* Correspondence: Nathan.Tintle@dordt.edu
2
Department of Mathematics and Statistics, Dordt College, 498 4th Ave. NE,
Sioux Center, IA 51250, USA
Full list of author information is available at the end of the article

frequently throughout the genome and have been
linked to both single-nucleotide polymorphisms (SNPs)
and epigenetic changes [2].In particular, DNA methylation may lead to different influences on gene activities
depending on the surrounding genetic sequence [3].
Because SNPs near the CpG site may alter methylation
levels, the statistical interaction between SNPs and
CpG sites may explain varying gene expression across
individuals. Prior research shows that DNA methylation
in the interleukin-4 receptor is associated with asthma,
but this association is further explained by the presence
or absence of a nearby SNP [4]. A study focusing on
obesity found the interaction between CpG sites in an
enhancer region interacts with CpG creating SNP sites
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in an obesity-risk haplotype, which helps explain obesity/
Type 2 Diabetes [5].
As part of GAW20, we were provided access to a data
set of methylation, SNPs, and triglyceride levels over 2 time
periods, along with numerous related covariates. In particular, the study measured triglyceride levels before and
after pharmaceutical intervention. Given the well-known
relationship between triglycerides and many different cardiometabolic diseases, including cardiovascular disease [6],
we chose to look for evidence of methylation at CpG sites
that potentially modulate the impact of nearby SNPs on
changes in triglyceride levels.
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for each SNPj, CPGj pair using the lm function in R [7]. In
particular, the second stage model for SNPj, CPGj pair was:
r j ¼ βS j SNP j þ βC j CPG j þ βS j C j SNP j CPG j

ð1Þ

where βS j C j is the estimate of interaction effect between
SNPj and CPGj. SNPj, CPGj pairs were made by assigning
each SNP passing QC to its nearest CpG site, resulting
in approximately 700,000 pairs, with some CpG sites
assigned to multiple SNPs.
Statistical analysis

Methods
Sample population and variables

The sample consisted of 670 individuals from a pedigree
sample provided as part of GAW20 for whom all
analyzed variables were available. We considered 6 covariates (age, observation center, smoking status, mass
spectrometry DX client [MSDX] International Diabetes
Federation [IDF] score, fasting time at baseline, and
high-density lipoprotein [HDL] at baseline) the majority
of which were significantly associated with baseline triglyceride (TG) in this sample. The primary response
variable of interest was TG level at baseline (visit 1 or 2).
For variables with up to 2 measurements at baseline
(HDL [baseline], TG [baseline]), we used the average
value if both measurements were available, or the only
available measurement if only one was available.
Models

The modeling process was done in 2 stages. The first
stage model resulted in a single residual TG value for
each person, while the second stage resulted in approximately 700,000 models (one for each SNP that passed
standard genome-wide association study [GWAS] quality control [QC] criteria: Hardy-Weinberg equilibrium
p value> 1 × 10− 6, minor allele frequency > 1%, SNP
missing data rate < 5%).
In the first stage, we used the lmekin function from
the coxme package in R [7] to predict the change in
log-transformed TG levels [y = ln (baseline)]. In cases
where 2 separate TG measurements were available for
the baseline, we natural-log (ln)-transformed the data
before averaging. Baseline ln-transformed TG levels was
predicted by the 6 covariates listed earlier and accounted
for the familial relationships in the model through the
use of the kinship matrix. We then saved the resulting
“residual” value (r i ¼ ^yi −yi ) for each of the i = 1,…, 670
individuals in our analysis.
The second stage predicted the residuals (ri′s) from stage
1 based on the number of minor alleles (SNPj = 0, 1, 2) and
methylation scores (CPGj ∈ [0, 1]) with a separate model

Statistical significance of the interaction term in Eq. 1
was assessed using an F test, essentially testing whether
the statistical interaction provided significantly more evidence of association with changes in TG levels versus a
model with only main-effects terms. Versions of Eq. 1
without the interaction term were also run. We started
by using a generally accepted, but stricter and conservative,
genome-wide significance level of 5 × 10− 8. We followed up
this analysis by using a more liberal and exploratory significance level of 1 × 10− 4 in our genome-wide
interaction analysis.
We followed this genome-wide analysis with a candidate
gene study focusing on 18 gene regions (containing 423
unique SNP-CpG sites) that have been shown to be associated with TGs in previous genome-wide association
studies via searches at http://www.ebi.ac.uk/gwas.
Throughout the candidate gene analysis, we used a significance level of 0.05. As part of the candidate gene analysis
we also collapsed all the CpG sites within each gene region (50 kb on either side of the gene) by using 5 different
methods (mean, minimum, maximum, median, and
sum-squares of the CpG values as the CPG value in the
model) to evaluate the potential impact of different ways
of summarizing methylation evidence for each SNP. For
the SNPs that demonstrated a significant interaction for
more than one of the collapsing methods used, we then
looked at the interactions between all CpG sites within
the region and those SNPs.

Results
Genome-wide approach

No interaction term p values were significant when
using the conservative 5 × 10−8threshold. However, 58
SNP-CpG pairs showed significant interactions using the
more liberal 1 × 10−4significance level. Table 1 summarizes 25 loci that include regions of SNPs that are colocalized and within genes (total of 44 interactions). The
median p value of the interaction term across all sites
was 0.504 and a lambda value of 1.02, showing no
inflation of test statistics.
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Table 1 Summary of 25 loci with significant interactions between SNP and CpG site at the 1 × 10−4significance levela
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Candidate gene approach

In our data, there are 18 genes (containing 423 SNPs for
which data was available) previously shown to be associated with TG levels. Table 2 summarizes the results of
fitting Eq. 1 with an interaction term, as well as a version
of Eq. 1 without the interaction term.
Thirteen of the 18 candidate genes show at least modest
(p < 0.05) evidence of statistical interaction between
nearby methylation values and SNPs within the gene. The
most significant SNP is in FADS3 (rs1675102) and has a
minor allele frequency of 0.28. The interaction is such that
additional copies of the minor allele lead to a decreased
impact of methylation on changes in TG levels.
Table 3 shows the results of collapsing all the CpG
sites within each gene region through the minimum
method, which uses the minimum CpG value of all CpG
sites within 50 kb of the gene. Compared to the other 4
methods, the minimum method resulted in more significant interactions (44) than did the other 4 collapsing
methods, which on average only have 23 significant interactions (detailed results not shown).
We identified 176 unique SNPs in significant interactions for more than 1 of the 5 different CpG collapsing
methods as found in Table 4. In total, there are 176 unique
significant SNP × CpG interactions. GALNT2 had the
largest number of significant results with 69 interactions,
where 1 of the 69 interactions is the most significant with
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a p value of 0.000142. The SNP in this interaction
(rs6677241) has a minor allele frequency of 0.026. The
interaction results in an increased impact of methylation on TG levels for every additional allele.

Discussion
Although no significant SNP–CPG interactions were
identified when using strict, genome-wide significance
thresholds (5 × 10− 8), use of a more exploratory approach
identified many genes previously shown to be associated
with cardiometabolic traits (1 × 10− 4). A candidate gene
approach, using a significance level of 0.05, identified loci in
13 genes with modest evidence for SNP-CpG interactions
on baseline TG levels. Furthermore, by using the collapsing
methods, we were able to identify potentially interesting
SNPs for additional exploration. Using only these SNPs,
our examination of all CpG sites within each gene region
resulted in 176 significant unique SNP-CpG pairs. In every
case, the SNP-CpGp value was smaller than both the SNP
and CpGp values from the noninteraction model. This
suggests that using SNP-CpG pairs may identify SNPs that
would not be identified by traditional GWAS techniques.
The gene GALNT2, had the most significant interactions
with 69. SNPs in GALNT2 were previously identified as associated with TG levels, high- and low-density lipoprotein
cholesterol [8]. One study shows that promoter methylation

Table 2 Summary of 18 genes with previous evidence of association with triglyceride levels
Gene

Chr

# of significant
interactionsa (total)

Smallest interaction
p value

SNP pvalueb

SNP location (bp)

Interaction (rs#:cg#)c

APOA1

11

1 (16)

0.0316

0.296

116,707,207

rs563838:cg24984312

APOA5

11

1 (12)

0.0316

0.296

116,707,207

rs563838:cg24984312

APOB

2

0 (13)

0.0511

0.124

21,318,003

rs312042:cg23349726

APOC3

11

1 (17)

0.0316

0.296

116,707,207

rs563838:cg24984312

BUD13

11

0 (13)

0.0866

0.904

116,570,686

rs1784042:cg19442415

CETP

16

1 (19)

0.0184

0.502

56,971,665

rs17241126:cg05062620

CLIP2

7

0 (2)

0.656

0.662

73,771,865

rs2718277:cg07814763

DOCK7

1

3 (75)

0.0261

0.341

63,034,240

rs12122434:cg00161770

FADS1

11

1 (16)

0.00430

0.740

61,581,397

rs444803:cg11606466

FADS2

11

1 (26)

0.00430

0.740

61,581,397

rs444803:cg11606466

FADS3

11

1 (20)

0.00351

0.830

61,710,585

rs1675102:cg16084190

GALNT2

1

2 (123)

0.0409

0.605

230,224,139

rs11588595:cg11424376

GCKR

2

1 (7)

0.0435

0.0846

27,730,170

rs17706100:cg22903471

LPL

8

1 (24)

0.0463

0.497

19,794,163

rs17091651:cg04035597

MLXIPL

7

0 (11)

0.106

0.373

73,083,725

rs884843:cg12958963

OTOR

20

1 (46)

0.0290

0.469

16,748,375

rs1883698:cg07500957

PLTP

20

2 (35)

0.0251

0.983

44,576,565

rs3795126:cg17262492

TRIB1

8

0 (8)

0.135

0.638

126,445,881

rs13255114:cg22644321

a

With a significance level of 0.05
b
From a model with only main effects terms for CpG and SNP (ie, Eq. 1 without the interaction term)
c
Duplicates are a result of the overlapping nature of several of the genes
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Table 3 Summary of CpG results after collapsing using the minimum method
Gene

Chr

# of significant
interactionsa(Total)

Significant SNPs
with > 1 methodsb

Smallest interaction
p value (rs#)

SNPp valuec

SNP location (bp)

# of CpGs within
region collapsed

APOA1

11

0 (45)

1

0.292 (rs633389)

0.381

116,667,337

57

APOA5

11

4 (43)

0

0.02564 (rs10488699)

0.00487

116,632,500

80

APOB

2

3 (43)

3

0.00286 (rs693)

0.0851

21,232,195

31

APOC3

11

0 (46)

0

0.111 (rs632153)

0.119

116,710,239

68

BUD13

11

5 (46)

2

0.0252 (rs12279373)

0.0155

116,600,400

63

CETP

16

4 (43)

0

0.0199 (rs247609)

0.984

56,973,461

47

CLIP2

7

1 (16)

1

0.0143 (rs4298392)

0.791

73,862,441

74

DOCK7

1

9 (38)

0

0.0215 (73862441)

0.306

63,049,819

39

FADS1

11

4 (18)

1

0.000440 (rs174534)

0.217

61,549,458

107

FADS2

11

3 (19)

1

0.00314 (rs174534)

0.214

61,549,458

109

FADS3

11

0 (21)

1

0.102 (rs7927548)

0.461

61,690,901

45

GALNT2

1

7 (138)

3

0.00154 (rs10779837)

0.194

230,327,568

96

GCKR

2

1 (9)

0

0.0480 (rs4665383)

0.0490

27,791,555

32

LPL

8

0 (53)

0

0.157 (rs10102876)

0.869

19,779,785

17

MLXIPL

7

0 (10)

1

0.0826 (rs7782054)

0.135

73,028,759

98

OTOR

20

0 (46)

3

0.0510 (rs16998203)

0.792

16,739,519

20

PLTP

20

3 (24)

0

0.0327 (rs11086984)

0.955

44,511,627

91

TRIB1

8

0 (32)

0

0.0802 (rs17663005)

0.798

126,464,388

38

a

With a significance level of 0.05
b
The SNP was found to be significant with more than 1CpG collapsing method. Refer to methods section
c
From a model with only main effects terms for CpG and SNP (ie, Model 1 without the interaction term)

of GALNT2 is associated with a higher risk of coronary
heart disease [9].
There are some limitations to our analysis. First, to
manage computational resources, we began by predicting baseline TG levels by kinship and covariates, yielding
residuals for each individual, which we used for assessing
impact of methylation and genetic variation. Other
alternatives to this methodology may exist. We used an
exploratory significance threshold for the genome-wide

analysis, relative to the vast majority of GWAS-type
analyses published today. Although this can lead to more
false-positive results, we did find a number of “subthreshold” loci of potential interest suggesting the need
for studies with larger sample sizes and more sensitive
statistical methods to draw out these loci of interest.
The minimum method of summarizing methylation in a
region nearby to a gene showed promise, although further work is needed to more fully evaluate the many

Table 4 Summary of 176a interaction pairs
Gene

Chr

# of significant
interactionsb(total)

Smallest interaction
p value

SNP pvaluec

CpG pvaluec

SNP location (bp)

Interaction (rs#:cg#)

APOA1

11

11 (57)

0.00678

0.591

0.310

116,759,824

rs12294191:cg07700644

APOB

2

9 (31)

0.00316

0.414

0.518

21,205,457

rs10172650:cg26118553

BUD13

11

31 (126)

0.00103

0.787

0.837

116,652,301

rs4417316:cg14371153

CLIP2

7

7 (74)

0.00318

0.214

0.983

73,671,288

rs3735504:cg08495433

FADS1

11

4 (52)

0.0193

0.0921

0.0831

61,549,458

rs174534:cg07689907

FADS2

11

10 (53)

0.00228

0.217

0.432

61,549,458

rs174534:cg11880646

FADS3

11

9 (45)

0.0183

0.861

0.690

61,698,488

rs7928792:cg03046346

GALNT2

1

69 (288)

0.000142

0.780

0.998

230,337,887

rs6677241:cg03961853

MLXIPL

7

16 (98)

0.00220

0.613

0.298

73,041,886

rs6460045:cg03842980

OTOR

20

10 (60)

0.00934

0.196

0.581

16,702,501

rs761228:cg07364906

a

As a result of overlap of gene regions for FADS1 and FADS2, 3 significant interactions are counted twice
b
With a significance level of 0.05
c
From models with only the main effect term for CpG or SNP. Refer to methods
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options. Regardless, leveraging prior biological evidence
(eg, via the candidate gene approach) may be of potential effect when testing for SNP–CPG interactions.

Conclusions
Even with “subthreshold” significance, our results go a
long way toward showing the need for statistical models
that leverage prior biological information. Our study
shows that a mediated effect of SNPs on methylation is
a possible explanation for changes in TG levels. With
this knowledge, more studies with greater sample sizes
can be performed as well as wet lab experimentation to
confirm the relationship. As we learn more about the
effect an individual’s genotype has on their health, there
is greater opportunity for personalized medicine to be
an effective treatment strategy.
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